Oral LUM-201 Growth Response Explored in Children with Prior rhGH-Treated GHD
Background
Idiopathic growth hormone deficiency (GHD) in children is characterized by insufficient secretion of growth hormone, leading to short stature. The current standard of care involves daily subcutaneous injections of recombinant human growth hormone (rhGH), which, while effective, can be burdensome for children and their families, potentially impacting adherence. This creates a significant unmet need for more convenient, non-invasive treatment options. LUM-201 is an investigational oral small molecule designed to stimulate endogenous growth hormone release, offering a potential paradigm shift from daily injections. This study specifically targets children who have already undergone a course of rhGH treatment, exploring LUM-201's efficacy in this specific population.
Study Design
This multi-national Phase 2 clinical trial, OraGrowtH213, evaluates the growth response to oral LUM-201 in children with idiopathic growth hormone deficiency (GHD). Participants previously completed a 12-month course of daily rhGH treatment in the LUM-201-01 trial. The primary objective is to assess LUM-201's efficacy in promoting growth in this cohort, likely via anthropometric measurements like height velocity. The study also aims to gather further safety and tolerability data for the oral compound.
Why It Matters
An effective oral treatment for growth hormone deficiency could significantly improve patient adherence and quality of life for children and their families. The burden of daily injections is a major factor in treatment discontinuation, and an oral alternative like LUM-201 could revolutionize GHD management. This Phase 2 study is crucial for understanding LUM-201's efficacy in a population already familiar with rhGH treatment, providing valuable data on its potential as a follow-on or alternative therapy. If successful, it moves closer to a more patient-friendly protocol, potentially reducing treatment fatigue and improving long-term outcomes for children with GHD.
lum-201
growth-hormone-deficiency
ghd
pediatrics
clinical-trial
phase-2
